Glutamate Receptor Antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Glutamate Receptor Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Glutamate Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glutamate Receptor Antagonist: Overview
Glutamate Receptor Antagonist can be broadly divided into two types: agents that block the NMDA receptor and those that block the AMPA receptor. Antagonists of the NMDA receptor act either by competitive antagonism at the glutamate-binding site or by noncompetitive antagonism at the glycine, phencyclidine (PCP)-, and magnesium-binding sites.
Preclinical, clinical, and other (e.g., genetic) evidence support the concept that migraine susceptibility may at least partially result from a glutamatergic system disorder. Therefore, the receptors of the glutamatergic system are considered relatively new targets for investigational drugs to treat migraine. Investigational and established Glutamate Receptor Antagonist (GluRAs) have been shown to possess antinociceptive properties in preclinical models of trigeminovascular nociception and have been evaluated in clinical trials.
Nicotine dependence is the primary motivational factor perpetuating the tobacco smoking habit that is one of the leading preventable causes of morbidity throughout the world. Metabotropic glutamate 5 receptor antagonists may be useful in decreasing the reinforcing effects of nicotine, reducing motivation for nicotine and preventing relapse during protracted abstinence, whereas metabotropic glutamate 2/3 receptor antagonists may alleviate the depression observed during the early nicotine withdrawal phase. Metabotropic glutamate 2/3 receptor antagonists may also be therapeutics for non-drug-induced depressions.
Report Highlights
This segment of the Glutamate Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glutamate Receptor Antagonist Emerging Drugs
It is currently in Phase III stage of development and is being developed by Eisai.
It is currently in Phase II stage of development and is being developed by Seelos Therapeutics.
Further product details are provided in the report……..
Glutamate Receptor Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Glutamate Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
Glutamate Receptor Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glutamate Receptor Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glutamate Receptor Antagonist drugs.
Glutamate Receptor Antagonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Glutamate Receptor Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Glutamate Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glutamate Receptor Antagonist: Overview
Glutamate Receptor Antagonist can be broadly divided into two types: agents that block the NMDA receptor and those that block the AMPA receptor. Antagonists of the NMDA receptor act either by competitive antagonism at the glutamate-binding site or by noncompetitive antagonism at the glycine, phencyclidine (PCP)-, and magnesium-binding sites.
Preclinical, clinical, and other (e.g., genetic) evidence support the concept that migraine susceptibility may at least partially result from a glutamatergic system disorder. Therefore, the receptors of the glutamatergic system are considered relatively new targets for investigational drugs to treat migraine. Investigational and established Glutamate Receptor Antagonist (GluRAs) have been shown to possess antinociceptive properties in preclinical models of trigeminovascular nociception and have been evaluated in clinical trials.
Nicotine dependence is the primary motivational factor perpetuating the tobacco smoking habit that is one of the leading preventable causes of morbidity throughout the world. Metabotropic glutamate 5 receptor antagonists may be useful in decreasing the reinforcing effects of nicotine, reducing motivation for nicotine and preventing relapse during protracted abstinence, whereas metabotropic glutamate 2/3 receptor antagonists may alleviate the depression observed during the early nicotine withdrawal phase. Metabotropic glutamate 2/3 receptor antagonists may also be therapeutics for non-drug-induced depressions.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glutamate Receptor Antagonist R&D. The therapies under development are focused on novel approaches for Glutamate Receptor Antagonist.
This segment of the Glutamate Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glutamate Receptor Antagonist Emerging Drugs
- E2007: Eisai
It is currently in Phase III stage of development and is being developed by Eisai.
- SLS-002: Seelos Therapeutics
It is currently in Phase II stage of development and is being developed by Seelos Therapeutics.
Further product details are provided in the report……..
Glutamate Receptor Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Glutamate Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Glutamate Receptor Antagonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Glutamate Receptor Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glutamate Receptor Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glutamate Receptor Antagonist drugs.
Glutamate Receptor Antagonist Report Insights
- Glutamate Receptor Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Glutamate Receptor Antagonist drugs?
- How many Glutamate Receptor Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Glutamate Receptor Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glutamate Receptor Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glutamate Receptor Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Algernon Pharmaceuticals
- Relmada Therapeutics
- Axsome Therapeutics
- Aptinyx
- Seelos Therapeutics
- Biohaven Pharmaceuticals
- Eisai
- NP-120
- REL-1017
- AXS-05
- NYX-458
- SLS-002
- BHV-5000
- E2007
Introduction
Executive Summary
Glutamate Receptor Antagonist : Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Glutamate Receptor Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Glutamate Receptor Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glutamate Receptor Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
E2007: Eisai
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
SLS-002: Seelos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
BHV-5000: Biohaven Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Glutamate Receptor Antagonist Key Companies
Glutamate Receptor Antagonist Key Products
Glutamate Receptor Antagonist - Unmet Needs
Glutamate Receptor Antagonist - Market Drivers and Barriers
Glutamate Receptor Antagonist - Future Perspectives and Conclusion
Glutamate Receptor Antagonist Analyst Views
Glutamate Receptor Antagonist Key Companies
Appendix
Executive Summary
Glutamate Receptor Antagonist : Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Glutamate Receptor Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Glutamate Receptor Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glutamate Receptor Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
E2007: Eisai
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
SLS-002: Seelos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
BHV-5000: Biohaven Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Glutamate Receptor Antagonist Key Companies
Glutamate Receptor Antagonist Key Products
Glutamate Receptor Antagonist - Unmet Needs
Glutamate Receptor Antagonist - Market Drivers and Barriers
Glutamate Receptor Antagonist - Future Perspectives and Conclusion
Glutamate Receptor Antagonist Analyst Views
Glutamate Receptor Antagonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glutamate Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glutamate Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glutamate Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glutamate Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
